Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Pathologic Complete Response 1Blastic Plasmacytoid Dendritic Cell Neoplasm 1

Interventions

venetoclax 1tegafur-gimeracil-oteracil 1tagraxofusp 1Surgical Procedures, Operative 1Radiation 1Oxaliplatin 1Observation 1Neoadjuvant Therapy 1Magnetic Resonance Imaging 1Leucovorin 1Irinotecan 1Induction Chemotherapy 1Immunotherapy 1Immune Checkpoint Inhibitors 1Folfox protocol 1Fluorouracil 1FOLFOXIRI protocol 1Endoscopy 1Drug Therapy 1Colonoscopy 1Chemoradiotherapy 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Pathologic Complete Response × tagraxofusp × Clear all
NCT07007052 2025-11-26

TAGVEN

French Innovative Leukemia Organisation

Phase 2 Not yet recruiting
33 enrolled
Myeloid

Pathologic Complete Response, Blastic Plasmacytoid Dendritic Cell Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡